menu search

Esperion's stock tumbles after disclosing dispute about milestone payment

Shares of Esperion Therapeutics Inc. ESPR plunged about 56% in premarket trading on Thursday, the day after the company told investors that there is a...

March 16, 2023, 8:21 am

Esperion therapeutics stock slumps 22% premarket as data from study of cholestrol-lowering drug fail to impress investors

The stock of Esperion Therapeutics Inc. ESPR, -0.31% slumped 22% in premarket trade Monday, as investors seemed to question whether data from a major ...

March 6, 2023, 6:52 am

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – ...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – ...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – ...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – ...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – ...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – ...

March 4, 2023, 3:30 pm

Esperion therapeutics: ready for growth ahead of clear outcomes topline data readout

Esperion Therapeutics recently reported their Q4 and full-year 2021 earnings. nexletol and NEXLIZET tog...

February 24, 2022, 12:37 pm

Esperion therapeutics: ready for growth ahead of clear outcomes topline data readout

Esperion Therapeutics recently reported their Q4 and full-year 2021 earnings. nexletol and NEXLIZET tog...

February 24, 2022, 12:37 pm

Esperion therapeutics: ready for growth ahead of clear outcomes topline data readout

Esperion Therapeutics recently reported their Q4 and full-year 2021 earnings. nexletol and NEXLIZET tog...

February 24, 2022, 12:37 pm


Search within

Pages Search Results: